Prospective isolation of human bone marrow stromal cell subsets: a comparative study between Stro-1-, CD146- and CD105-enriched populations by Gothard, David et al.
Journal of Tissue Engineering
Volume 5: 1 –17 
© The Author(s) 2014
DOI: 10.1177/2041731414551763
tej.sagepub.com
Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 
3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and 
distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page  
(http://www.uk.sagepub.com/aboutus/openaccess.htm).
Prospective isolation of human bone 
marrow stromal cell subsets:  
A comparative study between Stro-1-, 
CD146- and CD105-enriched  
populations
David Gothard, Joanna Greenhough, Esther Ralph and Richard 
OC Oreffo
Abstract
Stro-1 has proved an efficacious marker for enrichment of skeletal stem and progenitor cells although isolated 
populations remain heterogeneous, exhibiting variable colony-forming efficiency and osteogenic differentiation 
potential. The emerging findings that skeletal stem cells originate from adventitial reticular cells have brought two 
further markers to the fore including CD146 and CD105 (both primarily endothelial and perivascular). This study 
has compared CD146-, CD105- and Stro-1 (individual and in combination)-enriched human bone marrow stromal 
cell subsets and assessed whether these endothelial/perivascular markers offer further selection over conventional 
Stro-1. Fluorescent cell sorting quantification showed that CD146 and CD105 both targeted smaller (2.22% ± 0.59% 
and 6.94% ± 1.34%, respectively) and potentially different human bone marrow stromal cell fractions compared to 
Stro-1 (16.29%  ±  0.78%). CD146+, but not CD105+, cells exhibited similar alkaline phosphatase–positive colony-
forming efficiency in vitro and collagen/proteoglycan deposition in vivo to Stro-1+ cells. Molecular analysis of a number 
of select osteogenic and potential osteo-predictive genes including ALP, CADM1, CLEC3B, DCN, LOXL4, OPN, POSTN 
and SATB2 showed Stro-1+ and CD146+ populations possessed similar expression profiles. A discrete human bone 
marrow stromal cell fraction (2.04% ± 0.41%) exhibited positive immuno-labelling for both Stro-1 and CD146. The data 
presented here show that CD146+ populations are comparable but not superior to Stro-1+ populations. However, 
this study demonstrates the critical need for new candidate markers with which to isolate homogeneous skeletal 
stem cell populations or skeletal stem cell populations which exhibit homogeneous in vitro/in vivo characteristics, for 
implementation within tissue engineering and regenerative medicine strategies.
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Introduction
Skeletal stem cells (SSCs), originally described as colony-
forming unit-fibroblasts (CFU-Fs),1–3 comprise a multipo-
tent non-haematopoietic stem cell fraction within human 
bone marrow (HBM). SSCs offer an ideal cell source for 
bone tissue engineering strategies due to their self-renewal 
and multi-lineage differentiation capacity toward osteo-
blasts, chondrocytes and adipocytes.4–9 To date, SSC 
enrichment remains largely based on cell surface expres-
sion profile.10–15 Their expression profile appears complex, 
and to date, isolation of homogeneous SSCs remains to be 
demonstrated,16 since many markers thought of as SSC-
specific are in fact expressed on the surface of fibroblastic 
cells. However, it is unclear whether a true homogeneous 
bone stem cell is required for successful in vivo tissue 
regeneration. Indeed, Tilley et al.17 have studied host 
derived-condensed heterogeneous bone marrow implanted 
into patients undergoing surgery which demonstrated bone 
tissue formation. Thus, homogeneity may not be a prereq-
uisite for clinical advancement.
One surface marker that has shown robust enrichment 
for SSCs is the trypsin-resistant cell surface antigen 1 
(Stro-1).18–21 Stro-1+ populations exhibit enhanced CFU-F 
capacity and elevated osteogenic differentiation both in 
vitro and in vivo in comparison to unsorted human bone 
marrow stromal cells (HBMSCs).22–25 However, Stro-1-
enriched SSCs remain highly heterogeneous,26–29 reflected 
by their in vivo localisation and in vitro multipotency and 
behaviour, demonstrated by the work of MacArthur et al.30 
on Stro-1 distribution and subpopulation behaviour in het-
erogeneous cell cultures of HBM.
Two alternative enrichment markers comprising mela-
noma cell adhesion molecule (MCAM; CD146) and 
Endoglin (CD105) have been identified on the cell surface 
of isolated populations exhibiting a significant fold 
increase in CFU-F capacity and in vitro osteogenic differ-
entiation.31–33 CD146 and CD105 are both primarily 
endothelial cell markers, but have previously been shown 
to target perivascular cells. Both markers have attained 
significant interest on the premise that SSCs originate 
from a sub-endothelial or perivascular niche. There is 
emerging evidence within the musculoskeletal field that 
SSCs originate from adventitial reticular cells.34,35 
However, it remains to be ascertained whether either of 
these markers are indeed SSC-specific and, at present, 
whether these markers offer improved SSC isolation com-
pared to conventional Stro-1.
In this study, we have compared CD146 and CD105 
with conventional Stro-1-enriched populations. Self-
renewal and growth potential within resultant populations 
were assessed by colony-forming efficiency (CFE) assay 
and alkaline phosphatase (ALP) expression. Isolated pop-
ulations were also examined under differentiation culture 
conditions and analysed by real-time polymerase chain 
reaction (rtPCR) analysis for differences in gene expres-
sion profiles. Analysis has focussed on traditional osteo-
genic genes and newer potentially osteo-predictive genes 
detailed by Larsen et al.36 In addition, in vivo growth and 
differentiation capacity were assessed following subcuta-
neous transplantation within MF1 nu/nu immunodeficient 
mice for 28 days.
This study demonstrates that CD146 and CD105 high-
light a smaller fraction of HBMSCs compared with Stro-1, 
and we hypothesised that the two markers may be target-
ing a subset of Stro-1+ populations. Consequently, Stro-1, 
CD146 and CD105 were utilised individually and in com-
bination (dual labelling) to isolate populations for com-
parative analysis. Dual labelling provided a tool to dissect 
and further interrogate the reported heterogeneous nature 
of Stro-1+ populations. CD146 has previously been shown 
to be co-expressed with Stro-1 on a subset of HBMSCs.37 
Furthermore, the dual marker approach has previously 
defined a putative primitive SSC population using Stro-1 
and CD106, clearly demonstrating an advantage over sin-
gle markers.18 The aim of these studies was to determine 
whether CD146+ and/or CD105+ populations were com-
parable or different to Stro-1+ populations. Clarification 
through comparison of the current accepted SSC markers 
may eventually help elucidate a select surface expression 
profile which identifies either the true bone stem cell or 
minimally a SSC population exhibiting enhanced homoge-
neous in vitro/in vivo characteristics.
Methods and materials
All reagents were supplied by Sigma–Aldrich unless oth-
erwise stated.
Ethics statement
These studies were conducted under ethical approval – 
LREC 194/99 (National Research Ethics Service – 
Southampton and South West Hampshire Research Ethics 
Committee) including Professional Indemnity and Clinical 
Trials Insurance. Written informed consent from each 
donor or their next of kin was obtained for use of samples 
in the research.
Bone marrow preparation and cell culture
Donated HBM was collected during routine total hip-
replacement surgery from haematologically normal osteo-
arthritic and trauma patients at the Southampton General 
Hospital. Samples were suspended in modified Eagle’s 
medium–alpha (α-MEM) and centrifuged to remove fat. 
The cell pellet was suspended in 20 mL α-MEM and passed 
through a 40-µm sieve to remove bone fragments and blood 
clots. The cell suspension was then carefully loaded on top 
of Lymphoprep™ (Lonza) and centrifuged for 40 min at 
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2200 r/min and 18°C to remove red blood cells. A buffy 
layer above the Lymphoprep containing mononuclear cells 
was washed with phosphate buffered saline (PBS; Lonza) 
and suspended in basal culture media (α-MEM, 10% foetal 
calf serum (FCS), penicillin (100 U/mL) and streptomycin 
(0.1 mg/mL)).
Cell isolation – immunocytochemistry
Freshly prepared HBM cells were washed in PBS, sus-
pended in blocking buffer (α-MEM, 10% human serum, 
5% FCS and 10 mg/mL bovine serum albumin (BSA)) and 
incubated at 4°C for 15 min. Cells were then incubated 
with primary antibody solution (1:50), washed three times 
with isolation buffer (1% BSA, in PBS) and incubated 
with magnetic and/or fluorescent-conjugated secondary 
antibody solution (1:200). Antibody incubations were 
60 min at 4°C under dark conditions diluted in isolation 
buffer.
Quantification. Immuno-labelled populations were quantified 
by flow cytometry (Guava easyCyte; Millipore) (Figure 2). 
Following immuno-labelling as described previously, 
1 × 106 cells were fixed in 4% paraformaldehyde (PFA in 
dH2O/PBS), washed in PBS and suspended ready for 
analysis. Flow cytometry analysed 5000 events, and 
thresholds were set according to both negative and 
isotype controls. Data are presented as mean ± standard 
deviation (SD).
Magnetic-activated cell sorting (single-labelled cells). Cell sus-
pensions were divided into four populations comprising a 
control non-labelled fraction and Stro-1 (neat (mouse IgM) 
– ‘in-house’ Hybridoma), CD146 (1:50 (mouse IgG) – BD 
Biosciences (clone: 1MCAM)) and CD105 (1:50 (mouse 
IgG) – BD Biosciences (clone: 35/CD105)) immuno-
labelled fractions. Following primary antibody adhesion 
and washing, cells were incubated with both magnetic 
(200 µL – anti-mouse IgM and IgG microbeads; Miltenyi 
Biotec) and fluorescent (1:200 – AlexaFluor 488–conju-
gated anti-mouse IgM and IgG and AlexaFluor 546–conju-
gated anti-mouse IgG; Invitrogen) secondary antibodies. 
Isolation was by magnetic cell sorting.
Fluorescent cell sorting (dual-labelled cells). Cell suspen-
sions were divided into four populations comprising a 
control non-labelled fraction and Stro-1/CD146 (neat 
Hybridoma/1:50 clone: 1MCAM), Stro-1/CD105 (neat 
Hybridoma/1:50 clone: 35/CD105) and CD146/CD105 
(1:50 clone: 1/MCAM/1:50 (rabbit IgG) – Novus Bio-
logicals) immuno-labelled fractions. Following incuba-
tion with primary antibody combinations and washing, 
cells were incubated with fluorescent (1:200, AlexaFluor 
488–conjugated anti-mouse IgM and AlexaFluor 
546–conjugated anti-mouse IgG (Stro-1/CD146 and 
Stro-1/CD105) and AlexaFluor 488–conjugated anti-
mouse IgG and AlexaFluor PE/647–conjugated anti-rab-
bit IgG (CD146/CD105)) secondary antibodies. Isolation 
was by fluorescent cell sorting (FACSAria; Becton 
Dickinson) and FACS Diva software version 5.0.3.
Visualisation. Post isolation, a small proportion of each 
immuno-labelled population was seeded onto tissue cul-
ture plastic, allowed to adhere, fixed and imaged by fluo-
rescence microscopy after 4′,6-diamidino-2-phenylindole 
(DAPI) counterstaining.
HBMSC populations were processed, immuno-labelled 
and sorted by magnetic-activated cell sorting (MACS) or 
fluorescent-activated cell sorting (FACS) as appropriate 
prior to in vitro expansion. Single-labelled populations 
were isolated by MACS due to the potential for bulk sepa-
ration. However, MACS cannot be used to isolate dual-
labelled populations as the system is not selective for A+/
B+ from A+/B− and A−/B+ populations. Data presented for 
fraction percentages are an average from three to five indi-
vidual patient-derived samples. Important to note here is 
that triple labelling was initially also investigated, but pre-
liminary quantification by flow cytometry suggested tri-
ple-labelled cells constituted <1% HBMSCs and isolation 
by conventional FACS was unsuccessful in our hands.
Unselected cells were utilised as control populations for 
comparison and authentication of marker enrichment. 
However, it is important to note that unselected popula-
tions contained both target and non-target cells in combi-
nation. Therefore, comparison with immuno-selected 
populations should be interpreted on the premise of enrich-
ment (removal of non-target cells), not comparison with a 
true negative control (negative fractions following target 
cell depletion). Indeed, the data presented here could be 
described as an assessment of non-stem cell–stem cell 
interaction and the effect on stem cell properties in culture, 
where immuno-selection offers increasing depletion of the 
non-stem cell fraction within HBM. Consequently, the aim 
of this study was not to achieve 100% purity (in the 
absence of specific markers), but rather use conventional 
isolation methods to enrich cell populations expressing 
Stro-1, CD146 and CD105 alone and in combination, rep-
resentative of those equivalent populations previously 
published within the literature, and characterise for direct 
comparison.
CFE assay and ALP expression
Isolated cell samples were counted using a haemocytome-
ter and seeded in tissue culture flasks with basal media at 
either 102 (P2 cultures – dual-labelled) or 103 (P0 cultures 
– single-labelled) cells/cm2 within T25-cm2 flasks. Cultures 
were PBS washed after 3 h and incubated at 37°C and 5% 
CO2 in a humidified atmosphere for 14 days without media 
change. Flasks were then fixed with 85% ethanol in dH2O. 
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Fixed cultures were air dried and then incubated with Fast 
Violet B salt (2.5 µg/mL) and Naphthol AS-MX phosphate 
(40 µL/mL) in dH2O for 30–45 min at 37°C and 5% CO2 in 
a humidified atmosphere under dark conditions. Cultures 
were washed with dH2O and counterstained with haema-
toxylin for 5 min at room temperature.
MACS separation usually demonstrates approximately 
70% purity, therefore non-labelled cells and potentially 
labelled non-mononuclear cells would have been present, 
both adding to the end cell count, but which may not have 
had the potential for colony formation. FACS separation 
demonstrated approximately 80%–85% purity. Seeding 
densities chosen were based on previous work within the 
group which initially investigated a range of densities 
including 0.5 × 101, 1 × 101, 1 × 102 and 1 × 103 cells/cm2. 
A seeding density of 103 cells/cm2 for MACS-separated P0 
cultures was found to generate sufficient numbers of colo-
nies for accurate quantification. A lower seeding density of 
102 cells/cm2 for FACS-separated P2 cultures was chosen 
as higher densities resulted in confluent monolayer growth, 
possibly due to emergence of a clonogenic phenotype dur-
ing in vitro expansion. Higher seeding densities for assess-
ment of clonogenic capacity, compared to other published 
studies, were used to accommodate for incorporation of 
non-mononuclear cells within the initial cell count of 
MACS-separated populations. ALP expression was quan-
tified as a relatively simple and routine indicator, but not 
predictor, of osteogenic differentiation potential. Colonies 
comprising ≥50 cells in distinct clusters and/or ≥50% 
ALP+ cells were counted. Single and dual CFE data were 
collected from four patient samples. The number of cells 
isolated and collected following FACS was too low to 
quantify reliably, and therefore, seeding densities could 
not be ascertained. All cells were culture expanded (P0); 
however, limited cells were cultured as colonies rather 
than monolayers. Colonies were subsequently passaged 
and reseeded (P1). Once monolayers were established and 
cell numbers were sufficient for quantification, flasks were 
seeded for colony growth analysis (P2 – CFE assay).
Differentiation culture
Isolated cell populations were cultured to approximately 
80% confluency in media, trypsinised and seeded into four 
individual culture flasks. Flasks were incubated in basal 
(α-MEM, 10% FCS) or differentiation media (α-MEM, 
10% FCS, 10 nM dexamethasone and 100 µM ascorbate-
2-phosphate) for 10 and 21 days at 37°C and 5%CO2 in a 
humidified atmosphere. Cultures received twice weekly 
media changes.
Single-labelled populations were placed under basal 
and differentiation media conditions at P1. Dual-labelled 
populations required additional in vitro expansion and 
therefore were cultured to P2 before basal and differentia-
tion conditions were applied.
Quantitative rtPCR
RNA isolation. At days 10 and 21 of culture, sorted popula-
tions were treated with Collagenase IV (1 mg/mL α-MEM) 
for 1 h at 37°C to digest extensive matrix deposition before 
PBS washing and incubation on ice in 1 mL Trizol® rea-
gent for 2 min. Cell scrapers were used to detach any 
remaining cells from the culture flasks and resultant Trizol 
suspensions were stored at −80°C. Samples were incu-
bated at room temperature with 200 µL chloroform for 
2–3 min prior to centrifugation at 13,000 r/min for 15 min 
(4°C). Phase separation resulted in protein at the bottom, 
DNA in the middle and RNA at the top. Top aqueous 
phase was added to 500 µL isopropanol and incubated at 
room temperature for 10 min before further centrifugation 
at 12,000 r/min for 10 min (4°C). Precipitated RNA pellets 
were washed in 75% ethanol before dissolution in ultra-
pure H2O. RNA concentration was evaluated using a Nan-
oDrop 1000 spectrophotometer (Thermo Scientific).
Complementary DNA synthesis. RNA was subjected to 
DNAse treatment using a Zymo RNA clean-up kit (Cam-
bridge Bioscience). A volume of 2 µg of RNA per sample 
was reverse transcribed to form complementary DNA 
(cDNA) using a SuperScript kit (Invitrogen) and stored at 
−20°C. Manufacturer protocols were employed for both kits.
rtPCR. cDNA was analysed using a 7500 Real-Time PCR 
System (Applied Bioscience) and accompanying soft-
ware, in a reaction volume of 24 µL per gene (forward and 
reverse primers 5 µL each (Sigma–Aldrich or DNA Tech-
nology, Denmark), SYBR Green 12.5 µL and ultra-pure 
H2O 6.5 µL). cDNA samples were analysed for expres-
sion of a panel of traditional osteogenic genes including 
ALP and osteopontin (OPN) and novel osteo-predictive 
genes including Cell Adhesion Molecule 1 (CADM1),38 
C-type lectin domain family 3, member B (CLEC3B; 
DNA Technology), Decorin (DCN; DNA Technology), 
Lysyl oxidase–like protein 4 (LOXL4; DNA Technology), 
Periostin (POSTN; DNA Technology) and Special AT-rich 
sequence Binding protein 2 (SATB2).36,39 Housekeeping 
(β-actin) and negative control genes Cathepsin C (CTSC; 
DNA Technology) and Myxovirus Resistance 1 (MX1; 
DNA Technology) were also assessed (Figure 1).40,41 
CTSC and MX1 were chosen due their upregulation within 
non-bone-forming HBMSC-telomerase reverse tran-
scriptase (HBMSC-TERT) cell populations.36 However, 
an important note to make is that a recent study has 
reported MX1 expression in an osteo lineage-restricted 
HBMSC subset.42 Consequently, MX1 data were not 
included here. Relative expression levels were normalised 
to the housekeeping gene β-actin. The comparative CT 
method was employed to quantify expression levels, 
where basal unsorted samples were assigned a value of 1 
and all other groups were determined relative to this 
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Figure 1. Gene primers for rtPCR. β-actin was used as the housekeeping gene for sample standardisation. Traditional osteogenic 
marker genes included ALP and OPN. Potential osteo-predictive genes included CADM1, CLEC3B, DCN, LOXL4, POSTN and SATB2. 
Inflammatory marker CTSC was used as a negative control.
rtPCR: real-time polymerase chain reaction.
Figure 2. Quantification of marker expression within HBMSC populations. Adult human bone marrow was fluorescently 
immuno-labelled with antibodies against Stro-1, CD146 and CD105 (a) individually and (b) in combination prior to quantification 
by flow cytometry. (a) x-axis depicts fluorescence intensity (logarithmic scale) and y-axis depicts cell count. (b) x- and y-axes depict 
fluorescence intensities (logarithmic scale) of each marker used for immuno-labelling. The red linear markers indicate the threshold 
for positive fluorescent labelling (assessed by negative controls). The green line in single marker populations indicates non-immuno-
labelled control cells. Additional line depicts immuno-labelled populations.
HBMSC: human bone marrow stromal cell.
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group. Duplicates were performed for all groups across all 
patient samples (three patients for dual populations and 
four patients for single populations).
Gene expression profiles of isolated populations were 
investigated to compare and assess the validity of isola-
tions representing distinct fractions of HBMSCs capable 
of osteogenic differentiation in vitro. ALP and OPN were 
selected as standard markers of osteogenic differentia-
tion.43–45 CADM1 is an osteo-progenitor surface marker.38 
Mutated or knocked out SATB2 has been shown to corre-
late with skeletal defects in vivo,40,41 and reduction in the 
SATB2 protein leads to lower osteogenic gene expres-
sion.46 CLEC3B, DCN, LOXL4 and POSTN were chosen 
following their identification as potential osteo-predictive 
genes within bone-forming HBMSC-TERT cells by Larsen 
et al.,36 while immune regulatory gene CTSC was selected 
as a control following identified upregulation within non-
bone-forming HBMSC-TERT cells.
In vivo differentiation
Diffusion chambers were constructed with Durapore™ 
membrane filters (hydrophilic polyvinylidene fluoride 
(PVDF) membrane; Merck Millipore) glued either side of a 
Plexiglas® ring (10 mm × 2 mm; diameter × thickness; 
Merck Millipore) and filled with 5% hydroxyapatite-loaded 
poly-lactic acid (HA-PLA) granules (molecular weight 
56 kDa, porous supercritical CO2 synthesised foamed scaf-
fold; gift from Dr Lisa White and Prof. Kevin M. 
Shakesheff). Confluent cell cultures were trypsinised (1% 
in PBS), suspended in basal media and seeded at 5 × 105 
cells per diffusion chamber47 prior to dorsal subcutaneous 
implantation within male MF1 nu/nu immunodeficient 
mice (Harlan) midway between the front and hind legs 
either side of the spine. Chambers were incubated for 
28 days (four chambers per mouse) without osteoinduction. 
Upon harvest, chambers were fixed in 4% PFA for 24 h and 
incubated in 20 mL rapid demineralisation buffer (4 M for-
mic acid and 0.5 M sodium formate in dH2O, pH 2.15) at 
4°C for 3 days to ensure smooth sectioning. Once deminer-
alised, samples were removed from the Plexiglas ring and 
methanol dehydrated (50%, 70% and 90% in H2O, and 
2 × 100%; 45–60 min each) before transfer to Histo-Clear 
(National Diagnostics). Samples were then incubated in 
paraffin wax at 60°C for 1 h before being embedded in wax 
blocks using an automated Shandon Citadel 2000 ready for 
histological assessment. Demineralisation of all samples 
was confirmed using Faxitron analysis.
PLA granules were used as a biocompatible scaffold to 
support cell growth within diffusion chambers. A volume 
of 5% HA was incorporated for osteoconductivity, opti-
mised to a level whereby scaffolds could be foamed and 
later cut to size: higher concentrations generated scaffolds 
that could not be easily cut to size and shape. Implanted 
cell numbers reflected in vitro proliferation within a single 
passage. Single-labelled populations were isolated from 
four patient samples, while dual-labelled populations were 
isolated from three patient samples. Single-labelled popu-
lations and control unselected cells were each seeded in 
four separate chambers and all implanted subcutaneously 
within one mouse. A second mouse had corresponding 
dual-labelled populations and control unselected cells 
implanted within four separate chambers. This was 
repeated for each patient sample. Chambers were incu-
bated in vivo for a period of 28 days as previous work has 
shown this time period to be sufficient for both cartilage 
and bone formation and was cost-effective.48 Harvested 
chambers were demineralised before histological analysis 
to improve sectioning as non-demineralised samples were 
found to tear sections. The diffusion chamber delivery sys-
tem was employed to assess in vivo growth and differen-
tiation capacity of isolated cell populations absent 
confounding host tissue invasion and complicating vascu-
lature, as both may mask results originating from the iso-
lated populations. The diffusion chamber does, however, 
allow movement of liquids, gases and nutrients across the 
permeable PVDF Durapore membranes which would 
allow for potential exogenous osteoinduction.
Histology
Paraffin-embedded diffusion chambers were sectioned at a 
thickness of 7 µm using a Microm HM330 D-6900 
microtome (Heidelberg Instruments). Eight cross sections 
at 40–50 section intervals were collected on Superfrost 
glass slides (Thermo Scientific), representing approxi-
mately 50% of the total chamber. All sections were subse-
quently stained with Alcian Blue (0.5% w/v in 3% acetic 
acid)/Sirius Red (1% w/v in saturated picric acid) (A/S) for 
proteoglycan and collagen deposition, to indicate growth 
and matrix production in vivo.
Alcian Blue/Sirius Red. Sectioned samples were de-waxed in 
Histo-Clear and rehydrated through a series of reverse 
methanol washes. Slides were then incubated through a 
series of solutions at room temperature including haema-
toxylin (10 min), acid/alcohol dip, Alcian Blue (10 min), 
molybdophosphoric acid (3% w/v in dH2O, 10–20 min) 
and Sirius Red (45–60 min). After each incubation step, 
the slides were rinsed with H2O. Once stained, slides were 
methanol/Histo-Clear dehydrated and mounted with DPX.
Quantification. A/S-stained sections were photographed 
using an Olympus dotSlide microscope and accompanying 
OlyVIA software. Collagen and proteoglycan deposition 
within each section were quantified using an overlaid 150-
µm square grid. The number of squares containing red col-
lagen, blue proteoglycan, or both were counted and 
represented as a percentage of the total number of squares 
covering all tissues. An average was calculated across each 
set of eight sections and from all patients for comparison 
between isolated populations. Digital image analysis was not 
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pursued due to inconsistencies in strength of stain presenting 
difficulties for software programs to analyse robustly. Spec-
trophotometric quantification of retrieved stain was not sen-
sitive enough to assess histological differences.
Statistical analysis
All data sets were tested for Gaussian distribution, deter-
mined by a Kolmogorov–Smirnov test. A Mann–Whitney 
test was performed to assess significance between individual 
unpaired non-parametric data sets. An unpaired t-test (Welch 
corrected) was performed to assess significance between 
individual unpaired parametric data sets. Significance was 
denoted by *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001.
Results
Identification and quantification of marker 
expression
Following routine sieving and Lymphoprep separation of 
HBM samples, HBMSCs were immuno-labelled with 
Stro-1, CD146 and CD105 antibodies, alone and in 
combination. FACS quantification of immuno-labelled 
HBMSC populations before in vitro expansion showed 
16.29% ± 1.73% expressed Stro-1, 2.22% ± 1.32% 
expressed CD146 and 6.94% ± 3.01% expressed CD105 
(Figure 2(a)). Dual-labelled populations constituted a 
smaller percentage of the whole HBMSC fraction with 
2.04% ± 0.71% expressing Stro-1/CD146, 3.05% ± 1.05% 
expressing Stro-1/CD105 and 0.68% ± 0.53% expressing 
CD146/CD105 (Figure 2(b)). Separated cells were left to 
adhere to tissue culture plastic before marker expression 
was visualised by fluorescence microscopy (Figure 3). 
HBMSCs exhibited expression of all three markers alone 
(Figure 3(a)–(c)) and in combination (Figure 3(d)–(f)). 
Populations sorted by MACS were quantified following 
isolation and recovered Stro-1 cells constituted 
12.52% ± 1.29% of the total number loaded, while CD146 
and CD105 cells constituted 3.75% ± 0.84% and 
5.06% ± 2.70%, respectively.
Isolated population purity following MACS separation 
was typically 70%, and following FACS separation, 
around 80%–85%. Ultimately, 100% pure population 
selection would require marker validation and application 
of single-cell sorting techniques such as a microfluidic 
approach.15 Higher isolation purity could be achieved by 
running the positively selected cell fraction through FACS 
for a second time. Previous experiments have shown purity 
to increase ≤90%. However, due to issues with cell viabil-
ity following second isolation runs, only a single FACS 
separation was employed. The central aim was enrichment 
of populations using the markers mentioned for compari-
son and assessment of whether CD146 or CD105 provided 
superior selection over Stro-1. Pivotal would then be 
robust culture methodology for the maintenance of cul-
tures, as in vitro expansion could lead to heterogeneous 
characteristic changes within isolated populations prior to 
any experimental investigation.
CFE assessment of marker-enriched 
populations
Following isolation, populations were assessed for clonal 
capacity by CFE assay. No significant differences were 
observed in total colony numbers between unsorted and 
single-labelled populations in the patients examined 
(Figure 4(a)). Stro-1- and CD146-enriched populations 
were comparable displaying significant enrichment for 
ALP+ colonies (1.79-fold Stro-1 ‘vs’ 1.74-fold CD146; 
p ≤ 0.05) over unsorted control samples (Figure 4(b)). 
Stro-1-/CD105- and CD146-/CD105-enriched populations 
also displayed significant enrichment in CFE (1.46- and 
1.70-fold, respectively) compared to unsorted control sam-
ples (Figure 4(c)). CD105- and Stro-1-/CD146-enriched 
populations did not show significant enrichment. Isolated 
dual populations from all four samples did not exhibit 
measurable ALP expression.
Interestingly, following MACS isolation of single-
labelled populations, negative fractions also demonstrated 
ALP+ colony formation. Negative fractions following 
Stro-1 isolation generated 54% ± 13% ALP+ colonies 
(average 50/91 colonies), while CD146 and CD105 nega-
tive fractions generated 45% ± 19% (average 22/49 colo-
nies) and 25% ± 3% ALP+ colonies (average 15/60 
colonies). Negative fractions following FACS isolation 
were not collected.
Although CD146- and Stro-1-enriched populations 
exhibited comparable ALP+ CFE capacity, total colony 
counts were not significantly different between all isola-
tions, suggesting the emergence of a clonogenic subpopu-
lation. However, 14-day culture reduces this likelihood 
and may therefore be due to high variability between 
patients and low sample numbers. Although negative frac-
tions following MACS isolation of single-labelled popula-
tions revealed a capacity for ALP+ colony formation at 
lower levels, this can be explained by differential marker 
expression between populations; Stro-1 negative fractions 
can express either or both CD146 and CD105 as can 
CD146 and CD105 negative fractions.
Gene expression analysis
Both single- and dual-labelled populations were cultured 
for 10 and 21 days in basal and differentiation media and 
analysed using rtPCR to assess gene expression.
Single-labelled populations. An elevation in ALP and reduc-
tion in LOXL4 expression were observed in all populations 
following 10 days of osteoinduction (Figure 5(a) and (f), 
8 Journal of Tissue Engineering 
Figure 3. Fluorescence imaging of cell surface markers. HBMSCs were immuno-labelled with antibodies against (a) Stro-1, (b) 
CD146, (c) CD105, (d) Stro-1/CD146, (e) Stro-1/CD105 and (f) CD146/CD105. Single-labelled populations were tagged with both 
magnetic antibodies for MACS separation and fluorescent antibodies for post-separation visualisation. Dual-labelled cells were 
fluorescently tagged for FACS separation. Post isolation, cells were seeded onto tissue culture plastic, allowed to adhere, fixed and 
imaged following DAPI counterstaining. Picture inserts show corresponding bright-field images.
HBMSC: human bone marrow stromal cell; MACS: magnetic-activated cell sorting; FACS: fluorescent-activated cell sorting; DAPI: 4′,6-diamidino-
2-phenylindole.
respectively). Reduction in LOXL4 expression continued 
to 21 days of osteoinduction (Figure 5(f)). Elevated ALP 
expression was not observed after 21 days of osteoinduc-
tion (Figure 5(a)). CD146- and CD105-enriched popula-
tions exhibited decreased ALP, LOXL4 and POSTN 
expression compared to unsorted and Stro-1-enriched 
populations after 10 days with and without osteoinduction 
(Figure 5(a), (f) and (g), respectively). However, decreased 
ALP expression was only observed within osteogenic cul-
tures (Figure 5(a)). Trends in ALP and POSTN expression 
between populations were not conserved after 21 days of 
osteoinduction (Figure 5(a) and (g), respectively). Only 
CD105-enriched populations exhibited decreased POSTN 
expression in response to osteoinduction (Figure 5(g)). 
Gothard et al. 9
Stro-1- and CD105-enriched populations exhibited 
increased CLEC3B expression in response to osteoinduction 
(Figure 5(d)). All isolated populations showed decreased 
OPN expression in response to osteoinduction after 21 days, 
although only Stro-1+ populations exhibited this same 
decrease after 10 days (Figure 5(b)). CADM1 exhibited 
decreased expression in both CD146- and CD105-enriched 
populations compared with Stro-1-enriched populations in 
both basal and osteogenic cultures after 10 days, but only in 
basal cultures after 21 days (Figure 5(c)). Osteoinduction 
resulted in decreased CADM1 expression within all popula-
tions. Under all conditions examined, no significant obser-
vations were noted between populations over time with and 
without osteoinduction in DCN and SATB2 expression 
(Figure 5(e) and (h)). Immune regulatory control gene 
CTSC displayed no significant differences between 
Figure 4. CFE assessment of isolated populations. (a and b) Following MACS isolation, single-labelled populations were seeded at a 
limiting dilution of 103 cells/cm2 within T25-cm2 flasks and cultured for 14 days. (c) Dual-labelled populations isolated by FACS were 
culture expanded to P2 prior to seeding at a limiting dilution of 102 cells/cm2 within T25-cm2 flasks and cultured for 14 days. Colony 
number and ALP expression were quantified and expressed as percentage ALP+ colonies. Dual-labelled populations, however, did 
not exhibit measurable levels of ALP expression. Consequently, dual-labelled population data are expressed as colony number only. 
Error bars are SD (*p ≤ 0.05).
CFE: colony-forming efficiency; MACS: magnetic-activated cell sorting; FACS: fluorescent-activated cell sorting; SD: standard deviation.
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populations over time, although osteogenic cultures did 
exhibit elevated expression compared to basal cultures in 
Stro-1- and CD105-enriched isolations (Figure 5(i)). Data 
were derived from four patient samples.
Dual-labelled populations. Dual-labelled populations dem-
onstrated a delayed response to osteoinduction with 
increased ALP expression visible at 21 days (Figure 6(a)). 
Stro-1-/CD146-enriched populations exhibited reduced 
CADM1 expression following 10 days of osteoinduction 
compared to unsorted populations (Figure 6(c)). Further-
more, only CD146-/CD105-enriched populations exhib-
ited elevated CLEC3B expression in response to 
osteoinduction for 10 days (Figure 6(d)). No reproducible 
significant differences were observed between dual-
labelled populations with and without osteoinduction in 
OPN, DCN, LOXL4, POSTN and SATB2 expression 
(Figure 6(b), (e)–(h), respectively). No significant differ-
ences in expression were observed in immune regulatory 
gene CTSC between populations with and without osteoin-
duction at day 21 (Figure 6(i)). However, higher CTSC 
expression in Stro-1-/CD146-enriched populations com-
pared to Stro-1-/CD105- and CD146-/CD105-enriched 
populations after 10 days without osteoinduction was 
observed (Figure 6(i)). Data were derived from three 
patient samples.
Histological assessment of in vivo function
Both single- and dual-labelled populations were cultured 
in vivo within sealed diffusion chambers implanted subcu-
taneously in MF1 nu/nu mice. Immunoselected popula-
tions generated new disorganised collagen matrix and 
proteoglycan deposition (Figure 7). Quantification via 
cross-sectional image analysis demonstrated a significant 
(p ≤ 0.01) increase in both collagen matrix production and 
proteoglycan deposition within Stro-1-, CD146- and 
CD146-/CD105-enriched populations compared to control 
unsorted populations (Figure 7(C)). Stro-1-/CD146-
enriched populations only exhibited enhanced proteo-
glycan deposition compared to unsorted populations 
(Figure 7(C)ii). Immunoselected CD105- and Stro-1-/
CD105-enriched populations were not significantly dif-
ferent to control unsorted populations in their capacity 
for collagen synthesis and proteoglycan deposition 
(Figure 7(C)).
Discussion
This study provides evidence that distinct cell populations 
can be isolated from HBM based on their expression of sur-
face markers Stro-1, CD146 and CD105 alone and in com-
bination.21,33,49 Stro-1 expression is considered a robust 
marker50,51 for the presence of functional SSCs within a 
given population, and alternative markers CD146 and 
CD105 enable interrogation of Stro-1-related heterogeneity. 
Marker-enriched populations exhibited proliferation and 
differentiation potential characteristic of SSCs compared to 
unsorted HBMSCs.52 Furthermore, this study indicates that 
these populations were functional in vivo, capable of gener-
ating new collagen matrix and proteoglycan deposition in 
the absence of host tissue and exogenous osteoinduction.
Heterogeneity within conventional Stro-1-enriched 
populations highlights the need for new markers to iden-
tify and target SSCs.16,28 Accumulating data for a perivas-
cular origin of SSCs has highlighted two enrichment 
markers, namely, CD146 and CD105.31–33 Interestingly, an 
alternative approach has identified HOP26, CD49a and 
SB-10 (non-perivascular specific) as potential SSC mark-
ers based on their expression within populations exhibiting 
enriched CFU-F capacity.53
FACS quantification demonstrated the potential of CD146 
and CD105, both alone and in combination, to target a smaller 
population within HBM than Stro-1 alone. However, not all 
CD146- and CD105-enriched cells co-expressed Stro-1, 
showing potential heterogeneity within these enriched popu-
lations. Indeed, only a fraction of CD146-enriched cells 
shared CD105 expression, and vice versa.54
Enrichment was assessed by CFE assay and ALP 
expression, both accepted markers of skeletal progenitor 
cells.2,55,56 However, ALP expression has not yet been 
proven as a predictor, rather a simple indicator of osteo-
genic potential.57 Although significant fold enrichment of 
ALP+ colonies was observed within isolated populations, 
all secondary CFE recorded here was of a significantly 
lower magnitude than previously published data (6%–
10%, compared with 30%–40% recorded by Lo Surdo and 
Bauer58 at P3). This may be accounted for by the fact that 
all HBMs used within this study were derived from donors 
over the age of 65 years. Indeed, D’Ippolitio et al.59 dem-
onstrated reduced ALP+ CFU-F capacity over increasing 
donor age. However, further clarification is required as 
other reports indicate that ALP+ CFU-F capacity was 
maintained across donor age, while Oreffo and col-
leagues60,61 found the number and percentage of ALP+ 
CFU-F showed a significant decrease in osteoporotic 
patients as compared with controls and osteoarthritic 
patients, indicating altered differentiation potential. 
Alternatively, CFE deficit may possibly be due to differ-
ences in protocol; a PBS wash 3 h after initial seeding pro-
vides inherent selection for the fast adherent cell fraction, 
thereby making CFE assessment across studies difficult.
In the population of patients examined, Stro-1-/CD146-
enriched cell populations did not display significantly 
increased CFE which contrasts with findings that CFU-F 
capable Stro-1-/CD146-enriched osteo-precursors can be 
isolated from periodontal ligament.49 A number of reasons 
may account for this observation, including prolonged in 
vitro expansion, population impurity, CFE ‘versus’ CFU-F 
assay, patient variability and different protocols. Where 
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Figure 7. Histological assessment of single- and dual-labelled population viability/function in vivo. (Ai and Bi) Unsorted, (Aii to Aiv) 
single- and (Bii to Biv) dual-labelled populations were expanded in vitro and seeded as a cell suspension into diffusion chambers at 
5 × 105 cells per chamber without osteoinduction. Chambers were implanted subcutaneously within MF1 nu/nu mice and incubated 
for 28 days. Following harvest, chambers were sectioned and stained with Alcian Blue/Sirius Red. Collagen and proteoglycan were 
identified and quantified by image analysis and represented as a percentage of the total sample (C). Overview images of the entire 
implant are shown on top (scale bar 500 µm). Large images underneath show enlarged regions (scale bar 50 µm). Highly magnified 
images are shown at the bottom (scale bar 10 µm). Error bars are SD (**p ≤ 0.01, ***p ≤ 0.001).
SD: standard deviation.
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Stro-1-/CD105-enriched populations showed increased 
CFE, CD105-enriched populations did not. The CD105-
enriched population is itself heterogeneous, and the CD105+/
Stro-1− fraction may elicit a negative effect on overall dif-
ferentiation potential. Significantly increased CFE within 
CD146/CD105-enriched populations supports their pub-
lished use as SSC markers.
Our studies indicate Stro-1- and CD146-enriched popu-
lations are capable of increased ALP+ colony formation, 
while Stro-1-/CD105- and CD146-/CD105-enriched pop-
ulations are capable of increased colony formation. The 
absence of ALP expression within all dual-labelled popu-
lations isolated by FACS may be attributable to additional 
in vitro culture expansion compared to single-labelled 
populations, which is known to affect cell proliferation 
and differentiation potentials with the emergence of a 
dominating fibroblastic phenotype.62–65
CD146- and CD105-enriched populations appeared to 
comprise lower proportions of osteo-responsive cells com-
pared to both unsorted and Stro-1-enriched populations 
due to their significant (p ≤ 0.05) decrease in ALP expres-
sion. Interestingly, Stro-1-enriched populations exhibited 
greater propensity for osteogenic differentiation suggested 
by increased expression of both early and late osteogenic 
markers following osteoinduction, POSTN and LOXL4, 
respectively. Stro-1-/CD146- and CD146-/CD105-enriched 
populations may comprise more osteo-responsive cells due 
to a reduction in CADM1 expression (early marker) and 
increase in CLEC3B expression (late marker). Taken 
together, the lack of more distinct gene expression profiles 
for OPN, DCN, LOXL4, POSTN and SATB2 between dual-
labelled populations may again be explained by the emer-
gence of a fibroblastic morphology,66–68 potentially through 
isolation impurity.69 Pro-inflammatory CTSC gene expres-
sion may explain low-level osteogenic gene expression as 
inflammation has previously been shown to down-regulate 
osteogenic differentiation.36,70,71
Osteochondral differentiation capacity is a prerequisite 
of SSCs, and as such, isolated populations were assessed in 
vivo using a MF1 nu/nu mouse model.72–75 Stro-1-, CD146- 
and CD146-/CD105-enriched populations exhibited 
enhanced collagen matrix production and proteoglycan dep-
osition (precursors to bone). Stro-1 and CD146 markers can 
both isolate HBMSC subsets with similar in vitro and in 
vivo characteristics, although enriched populations remain 
heterogeneous.76 Stro-1-/CD146-enriched populations did 
not exhibit significantly increased collagen deposition. 
However, significantly increased proteoglycan deposition 
was observed indicating a potential increase in cartilaginous 
differentiation and possible pre-osteoid formation. Given a 
longer in vivo period, this proteoglycan-rich matrix could 
develop toward immature osteoid and subsequently to 
mature mineralised bone, given the correct spatiotemporal 
developmental signals. The relationship between Stro-1 and 
CD146 therefore requires further investigation.
CD105-enriched populations, in this study, did not 
show elevated collagen synthesis and proteoglycan depo-
sition which correlated with their low ALP+ CFE. The 
closed nature of the diffusion chamber rather than an 
open system was pursued to eliminate haematopoietic 
marrow formation, as vascular infiltration compounds 
simple preliminary readouts. However, this may have 
hindered more advanced cartilage and bone formation 
often observed within a 28-day timescale. Additional 
studies would be required to elucidate this further since 
the pericytes lining marrow sinusoids are thought to be 
the SSC origin.34 It is possible that chambers contained 
sub-optimal cell numbers, limiting cartilage and bone 
formation.
Conclusion
This study has provided insight into the composition of 
heterogeneous HBMSC subsets using alternative and 
additional markers to Stro-1 including CD146 and 
CD105. Stro-1 is a robust SSC marker; however, isola-
tion using only Stro-1 expression generates heterogene-
ous populations. Here, we demonstrate Stro-1-enriched 
populations exhibited both enhanced ALP+ CFE and dif-
ferentiation capacity, expected of potential SSCs (the 
diminutive true bone stem cell fraction within conven-
tional heterogeneous mesenchymal stem cell popula-
tions), and that CD146-enrichment demonstrated 
equivalent enhancement, indicating a perivascular SSC 
origin. Interestingly, CD146-enriched populations con-
stituted a significantly narrower fraction (2.22%) of 
HBMSCs compared to Stro-1 (16.29%); however, heter-
ogeneity within these populations remains unclear. 
Although CD146 provides an alternative to Stro-1, nei-
ther CD146 nor CD105 provided superior SSC isolation. 
Therefore, Stro-1 remains an acceptable SSC marker; 
however, critical to note is the continued need for spe-
cific SSC markers which can isolate pure populations for 
bone biology investigation in vitro and clinical transla-
tion in vivo.
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